Clopidogrel preserves whole kidney autoregulatory behavior in ANG II-induced hypertension

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 6, 2014, Pages

  Osmond, David A ^a   Zhang, Shali ^a   Pollock, Jennifer S ^a   Yamamoto, Tatsuo ^b   De Migue, Carmen ^a   Inscho, Edward W ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Numazu City Hospital   (Japan)

Author keywords

Angiotensin II; Autoregulatory response; Clopidogrel; Lymphocyte; Purinergic p2y receptors; Thromboxane

Indexed keywords

ANGIOTENSIN II; CLOPIDOGREL; COLLAGEN TYPE 1; PENTOBARBITAL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; DRUG DERIVATIVE; PURINERGIC P2Y RECEPTOR; THROMBOXANE; THROMBOXANE B2; TICLOPIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERIAL WALL THICKENING; ARTICLE; AUTOREGULATION; CD3+ T LYMPHOCYTE; EXPERIMENTAL HYPERTENSION; GENERAL DEVICE; GLOMERULUS BASEMENT MEMBRANE; IN VIVO STUDY; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY FIBROSIS; KIDNEY TUBULE DAMAGE; LYMPHOCYTIC INFILTRATION; MALE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; RECEPTOR BLOCKING; RENAL ARTERY; RENOVASCULAR HYPERTENSION; SYSTEMIC THERAPY; ULTRASONIC FLOW PROBE; ANIMAL; AUTOREGULATORY RESPONSE; BLOOD; CHEMICALLY INDUCED DISORDER; HYPERTENSION; KIDNEY; KIDNEY CIRCULATION; LYMPHOCYTE; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ANGIOTENSIN II; AUTOREGULATORY RESPONSE; CLOPIDOGREL; LYMPHOCYTE; PURINERGIC P2Y RECEPTORS; THROMBOXANE;

ANGIOTENSIN II; ANIMALS; HYPERTENSION; KIDNEY; MALE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P2Y12; RENAL CIRCULATION; THROMBOXANE B2; TICLOPIDINE;

EID: 84900299138     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00444.2013     Document Type: Article

References (61)

1. Addi AB, Cammarata D, Conley PB, Boeynaems JM, Robaye B. Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP. J Immunol 185: 5900-5906, 2010.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55: 780-784, 2006.
3. Armstrong PCJ, Dhanji ARA, Tucker AT, Mitchell JA, Warner TD. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 8: 613-615, 2010.
4. Baylis C. Effects of administered thromboxanes on the intact, normal rat kidney. Renal Physiol 10: 110-121, 1987.
5. Bidani AK, Griffin KA, Williamson G, Wang X, Loutzenhiser R. Protective importance of the myogenic response in the renal circulation. Hypertension 54: 393-398, 2009.
6. Bobadilla NA, Tack I, Tapia E, Sanchez-Lozada LG, Santamaria J, Jimenez F, Striker LJ, Striker GE, Herrera-Acosta J. Pentosan polysulfate prevents glomerular hypertension and structural injury despite persisting hypertension in 5/6 nephrectomy rats. J Am Soc Nephrol 12: 2080-2087, 2001.
7. Boeynaems JM, Communi D, Robaye B. Overview of the pharmacology and physiological roles of P2Y receptors. WIREs Membr Transport Signal 1: 581-588, 2012.
8. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
9. Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: Further evidence that some cases of platelet "primary secretion defect" are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 20: e101-e106, 2000.
10. Cattaneo M, Lombardi R, Zighetti ML, Gachet C, Ohlmann P, Cazenave JP, Mannucci PM. Deficiency of (33P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Thromb Haemost 77: 986-990, 1997.
11. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 31: 53-59, 2003.
12. De Miguel C, Das S, Lund H, Mattson DL. T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 298: R1136-R1142, 2010.
13. Dey A, Williams RS, Pollock DM, Stepp DW, Newman JW, Hammock BD, Imig JD. Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. Obes Res 12: 1278-1289, 2004.
14. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM. TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol 294: R76-R83, 2008.
15. Elmarakby AA, Quigley JE, Olearczyk JJ, Sridhar A, Cook AK, Inscho EW, Pollock DM, Imig JD. Chemokine receptor 2b inhibition provides renal protection in Angiotensin II salt hypertension. Hypertension 50: 1069-1076, 2007.
16. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 107: 1591-1598, 2001.
17. Franco M, Tapia E, Santamaria J, Zafra I, Garcia-Torres R, Gordon KL, Pons H, Rodriguez-Iturbe B, Johnson RJ,. Herrera-Acosta J. Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol 12: 2263-2271, 2001.
18. Fukuda N, Tahira Y, Matsuda H, Matsumoto K. Transforming growth factor-β as a treatment target in renal diseases. J Nephrol 22: 708-715, 2009.
19. Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 108: 180-192, 2005.
20. Garovic V, Textor SC. Renovascular hypertension: current concepts. Semin Nephrol 25: 261-271, 2005.
21. Giachini FRC, Osmond DA, Zhang S, Carneiro FS, Lima VV, Inscho EW, Webb RC, Tostes RC. Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats. Clin Sci 118: 463-471, 2010.
22. Graciano ML, Nishiyama A, Jackson K, Seth DM, Ortiz RM, Prieto- Carrasquero MC, Kobori H, Navar LG. Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension. Am J Physiol Renal Physiol 294: F161-F169, 2008.
23. Graff J, Harder S, Wahl O, Scheuermann EH, Gossmann J. Antiinflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin Pharmacol Ther 78: 468-476, 2005.
24. Guan Z, Fuller BS, Yamamoto T, Cook AK, Pollock JS, Inscho EW. Pentosan polysulfate treatment preserves renal autoregulation in Ang II-infused hypertensive rats via normalization of P2X1 receptor activation. Am J Physiol Renal Physiol 298: F1276-F1284, 2010.
25. Guan Z, Giddens MI, Osmond DA, Cook AK, Hobbs JL, Zhang S, Yamamoto T, Pollock JS, Pollock DM, Inscho EW. Immunosuppression preserves renal autoregulatory function and microvascular P2X1 receptor reactivity in ANG II hypertensive rats. Am J Physiol Renal Physiol 304: F801-F807, 2013.
26. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460, 2007.
27. Herrera-Acosta J, Tapia E, Sanchez-Lozada LG, Franco M, Striker LJ, Striker GE, Rodriguez-Iturbe B. Restoration of glomerular haemodynamics and renal injury independent of arterial hypertension in rats with subtotal renal ablation. J Hypertens 20: S29-S35, 2002.
28. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG. Regulation of T cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 296: R208-R216, 2009.
29. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Comley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409: 202-207, 2001.
30. Ichihara A, Imig JD, Inscho EW, Navar LG. Interactive nitric oxide angiotensin II influences on renal microcirculation in angiotensin II induced hypertension. Hypertension 31: 1255-1260, 1998.
31. Imig JD, Inscho EW. Adaptations of the renal microcirculation to hypertension. Microcirculation 9: 315-328, 2002.
32. Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ. Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. J Clin Invest 112: 1895-1905, 2003.
33. Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ. Renal autoregulation in P2X1 knockout mice. Acta Physiol Scand 181: 445-453, 2004.
34. Inscho EW, Cook AK, Navar LG. Pressure-mediated vasoconstriction of juxtamedullary afferent arterioles involves P2-purinoceptor activation. Am J Physiol Renal Fluid Electrolyte Physiol 271: F1077-F1085, 1996.
35. Keen HL, Brands MW, Smith MJ, Shek EW, Hall JE. Thromboxane is required for full expression of angiotensin hypertension in rats. Hypertension 29: 310-314, 1997.
36. Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 73: 232-241, 2003.
37. Klinkhardt U, Kuczka K, Harder S. Effects of the NHE-1 inhibitor cariporide alone or together with the P2Y12 antagonist AR-C 69331 MX on CD62p expression and formation of platelet-leukocyte aggregates. Thromb Res 111: 251-257, 2003.
38. Kunapuli SP. Functional characterization of platelet ADP receptors. Platelets 9: 343-351, 1998.
39. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurement in humans and experimental animals: part 2: blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association. Hypertension 45: 299-310, 2005.
40. Luft FC, Dechend R, Müller DN. Immune mechanisms in angiotensin II-induced target-organ damage. Ann Med 44: S49-S54, 2012.
41. Mistry M, Nasjletti A. Role of pressor prostanoids in rats with angiotensin II-salt-induced hypertension. Hypertension 11: 758-762, 1988.
42. Molero L, Lopez-Farre A, Mateos-Caceres PJ, Fernandez-Sanchez R, Maestro ML, Silva J, Rodriguez E, Macaya C. Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol 146: 419-424, 2005.
43. Murphy RC, FitzGerald GA. Current approaches to estimation of eicosanoid formation in vivo. Adv Prostaglandin Thromboxane Leukot Res 22: 341-348, 1994.
44. Osmond DA, Inscho EW. P2X1 receptor blockade inhibits whole kidney autoregulation of renal blood flow in vivo. Am J Physiol Renal Physiol 298: F1360-F1368, 2010.
45. Peters H, Eisenberg R, Daig U, Liefeldt L, Westenfeld R, Gaedeke J, Kramer S, Neumayer HH. Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis. Kidney Int 65: 2238-2248, 2004.
46. Pollock DM, Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol 281: F144-F150, 2001.
47. Quintas C, Fraga S, Goncalves J, Queiroz G. The P2Y1 and P2Y12 receptors mediate autoinhibition of transmitter release in sympathetic innervated tissues. Neurochem Int 55: 505-513, 2009.
48. Roson MI, Cao G, Silvana DP, Gorzalczany S, Pandolfo M, Toblli JE, Fernandez BE. Angiotensin II increases intrarenal transforming growth factor-_1 in rats submitted to sodium overload independently of blood pressure. Hypertens Res 31: 707-715, 2008.
49. Savi P, Nurden AT, Nurden S, Levy-Toledano JM, Herbert P. Clopidogrel: a review of its mechanism of action. Platelets 9: 251-255, 1998.
50. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci 112: 375-384, 2007.
51. Schiffrin EL. T lymphocytes: a role in hypertension? Curr Opin Nephrol Hypertens 19: 181-186, 2010.
52. Schnermann J, Levine DZ. Paracrine factors in tubuloglomerular feedback: adenosine, ATP and nitric oxide. Ann Rev Physiol 65: 501-529, 2003.
53. Sharma K, Cook A, Smith M, Valancius C, Inscho EW. TGF-β impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol 288: F1069-F1077, 2005.
54. Storey RF. Biology and pharamcology of the platelet P2Y12 receptors. Curr Pharm Des 12: 1255-1259, 2006.
55. Storey RF. New P2Y12 inhibitors. Heart 97: 1262-1267, 2011.
56. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T, Briggs J, Schnermann J. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine A1 receptors. Proc Natl Acad Sci USA 98: 9983-9988, 2001.
57. Tu X, Chen X, Xie Y, Shi S, Wang J, Chen Y, Li J. Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury. J Am Soc Nephrol 19: 77-83, 2008.
58. Ueno M, Kodali M, Tello-Monoliu A, Angiolillo DJ. Role of platelets and antiplatelet therapy in cardiovascular disease. J Atheroscler Thromb 18: 431-442, 2011.
59. + stem and progenitor cells. BMC Immunol 5: 16, 2004.
60. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 24: 1810-1815, 2004.
61. Wilcox CS, Welch WJ, Snellen H. Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int 40: 1090-1097, 1991.